查看文章

Lymphoplasmacytic lymphoma (LPL) is a rare indolent B-cell malignancy characterized by an activating mutation of MYD88 (L265P), and is also known as Waldenstrom macroglobulinemia (WM) when producing a detectable serum IgM monoclonal protein. 1 LPL commonly causes cytopenias by bone marrow infiltration, and paraproteins can cause hyperviscosity syndromes and antibody mediated toxicities. Ibrutinib, which blocks the downstream effects of MYD88 activation by inhibiting Bruton’s tyrosine kinase (BTK), was recently approved by the US Food and Drug Administration (FDA) for treatment of LPL. 2, 3 There are published data on the use of ibrutinib to treat WM in clinical trials, 2, 4 but limited reported data on the use of ibrutinib to treat LPL in clinical practice (“real world experience”).

This observational study was conducted from January 2014 through December 2016 with institutional research board …